As many as 1 in 5 people won't lose weight with GLP-1 drugs, experts say
About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...
Allurion launches compounded GLP-1 program as FDA aims to end access
Allurion's new program uses artificial intelligence guidance to help patients adhere to a well-rounded diet and exercise ...
Opinion
Employee Benefit News3dOpinion
Why GLP-1 patients need access to behavioral health support
Obesity is associated with increased odds of mood and anxiety disorders, including more serious mental health conditions such as schizophrenia and bipolar disease.
Morningstar9d
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
Exenatide is a GLP-1 agonist indicated as an adjunct to diet and exercise to improve glycemic ... regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts ...
Rolling Out21d
8 remarkable benefits of GLP-1 medications for joint pain management
Recent clinical research has unveiled groundbreaking developments in the application of GLP-1 medications for managing joint-related discomfort. These findings represent a significant shift in ...
pharmaphorum4d
Innovent throws its hat further into China's GLP-1 ring
Now, Innovent has said it plans to file for NMPA approval of the drug in diabetes "in the near term." "Mazdutide is the first and fastest-developed [GLP-1/glucagon] dual agonist in the world ...
The Best Foods to Eat When Taking Wegovy for Weight Loss
Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...